Health
Daily oral GLP-1 medication linked to similar weight loss across three menopausal stages
New analyses to be presented at the annual meeting of the European Association for the Study of Diabetes ( EASD ) in Milan, Italy, Sept. 28–Oct. 2, show that orforglipron, a daily oral medication for weight loss and type 2 diabetes, was…
AI Summary
New analyses presented at the European Association for the Study of Diabetes (EASD) annual meeting in Milan show that the daily oral medication orforglipron, used for weight loss and type 2 diabetes, produced comparable weight loss in women across three menopausal stages—pre‑menopause, during menopause, and post‑menopause. The findings were reported by Dr. [author name not provided].
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- ADHD and autism appear more common among young people diagnosed with type 2 diabetesContinue reading
- Leg pain can warn of a serious condition: Why peripheral artery disease (PAD) needs more attentionContinue reading
- A protein-degradation mechanism opens a new treatment route for an inherited arrhythmiaContinue reading
- Beyond movement, the cerebellum may contribute to the anticipation of rewardsContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow